Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (30219)	1/13/2000 3:07:00 PM
From: Mudcat	Respond to of 32384

Could we be that lucky Bob

To: bob zagorin who wrote (30219)	1/13/2000 3:36:00 PM
From: Skeeter Bug	Read Replies (1) \| Respond to of 32384

>>look at VICL. stuck in doldrums as lomg as LGND and moved from 7-8 range to mid thirties in last 3 mos. this can happen here.<< bob, but i want $50! ;-)

To: bob zagorin who wrote (30219)	1/13/2000 6:07:00 PM
From: Hippieslayer	Respond to of 32384

bob, vicl moved up for a reason. Vicl has no approved drugs, a pipeline that isn't as well evolved (i believe), and a management team that might not quite stand up to ligands-but that might be debatable. my point is that comparing lgnd to vicl is futile. I know you are well meaning but vical started moving long before lgnd despite lgnd's good fortunes with the fda (which did nothing to help the stock) right now, the biotech sector is rising and most boats are sailing on the high seas. ligand, like other biotechs will have to show that they can get drugs on the market to sustain their price levels. ligand has gotten thru the door and now it's time to show the street that they can turn a buck (actually-if they can make a major score with their drugs) it's good to see ligand move but ther eis still a long road to travel for many biotechs.